Grassley:
Top priority is reducing health care costs
U.S. Senator Chuck
Grassley of Iowa
As
Americans, we’re blessed to live in a nation where investments and innovations
in health care help millions of people every day to manage and overcome their
illnesses. Yet the escalating prices of prescription drugs are a daily concern
for every American in need of them. In fact, it’s one of the top concerns I
hear from Iowans at my annual 99 county meetings as well as through phone calls
and emails.
For
years, I’ve spoken out about skyrocketing prescription drug costs. As a fiscal
conservative, I believe in strong intellectual property rights to incentivize
companies to invest in research and development. I also believe wholeheartedly
in free enterprise and the entrepreneurial spirit that drives innovation and
opens new frontiers of modern medicine. However, the government has a
responsibility to go after companies that engage in unfair business practices
and anti-competitive behavior that harms consumers and cheats taxpayers.
Congress
must have a fundamental commitment to transparency. Sunshine helps to shine
light on wrongdoing. It strengthens good government and bolsters the trust
between elected representatives and their constituents. I’ve worked across the
aisle to apply this standard throughout my time in the U.S. Senate,
particularly in the area of health care.
In
2016, Iowans contacted me regarding the increasing price of EpiPens. Families
throughout Iowa and across the country need this life-saving anti-allergy
medication but struggled to afford it after dramatic price hikes. That began a
years-long look into the cause of these increases. During the course of my
oversight efforts, I learned that EpiPen was misclassified in the Medicaid Drug
Rebate Program as a generic drug rather than a name-brand medication. That
misclassification may have resulted in taxpayers and states overpaying for
EpiPen by as much as $1.3 billion over 10 years. What’s worse, EpiPen is not
the only misclassified drug according to the U.S. Department of Health and
Human Services and the HHS Office of Inspector General.
The
fiasco concerning EpiPen and the Medicaid Drug Rebate Program is just one of
many examples where government oversight is critical to the protection of
taxpayers and the safety of American citizens.
My
work in the Senate has focused on helping Iowans receive the quality health
care they deserve. That has included oversight of elder care, increasing
transparency between drug companies and the hospitals and health care providers
that prescribe medications, as well as ensuring hospital payment programs are
effective and working as Congress intended, such as those in the 340B program.
As
chairman of the Senate Finance Committee, I’ll continue these efforts and build
upon the achievements of previous years in a bipartisan way. My top priorities
include lowering health care costs — including prescription drug costs,
increasing quality of care for seniors, addressing rural health care needs and
conducting rigorous oversight of the Affordable Care Act, the health
care nonprofit sector and executive federal health care agencies. Working
together, we can build bipartisan solutions that will greatly improve our
healthcare system.
I’ll
also continue to keep tabs on proposed buy-outs and mergers between
pharmaceutical companies, insurance companies and health care providers to
ensure that these transactions don’t weaken competition or negatively impact
health care consumers and taxpayers. I’ll continue to fight for greater transparency
by requiring companies to include drug prices in direct-to-consumer
advertising. The more information patients and health care providers have to
make decisions regarding prescription drugs, the better.
These
priorities are achievable through hard work and bipartisan cooperation. Last
Congress, I worked to introduce legislation with every Democratic member of the
Senate Finance Committee, and that spirit of bipartisanship will be a hallmark
of my chairmanship this Congress. I welcome input not only from my Democratic
colleagues in the Senate, but also the incoming Democratic House majority to
join our efforts to improve health care on behalf of Iowans and every American.
-30-